BARCELONA, Spain--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of data from ongoing clinical trials of darinaparsin (ZIO-101) to treat advanced hematological malignancies. The data were presented yesterday at the 14th Annual European Cancer Conference (ECCO) meeting being held in Barcelona, Spain. The ongoing studies, primarily in patients with advanced leukemia, are evaluating the safety and activity of intravenously administered darinaparsin.
